Clinical trials: Alopecia, Androgenetic
Alopecia, Androgenetic, Healthy
Assessment of Biological and Biometrological Parameters in Adult Subjects with Androgenetic Alopecia
Androgenetic alopecia is a chronic pathology affecting approximately 50% of men at 50 years old and is characterized by a progressive miniaturization of the hair follicle leading to a localized baldness.
- Trial name
- NCT06854432
- Testing
- Biometrological measurements, Biological sampling
- Where
- France
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Hair Loss, Hair Loss/Baldness
HairDx Analytical Validation Study
The HairDx Test reports genetic variants associated with the development of FPHL.
- Conditions
- Hair Loss, Hair Loss/Baldness, Female Pattern Baldness, Androgenetic Alopecia
- Trial name
- NCT04379583
- Testing
- HairDx Sample Collection Kit
- Where
- United States
- Sponsor
- Applied Biology, Inc.
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013)
The purpose of the study is to evaluate the ability of injections Ji Gami(TM) to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451073
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 6 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia
Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia
This study will be a single center, open-label study of a single concentration of ANR- 001.1. The solution will be applied to the scalp of 14 male subjects by study staff once daily for 7 days.
- Trial name
- NCT05864885
- Testing
- Minoxidil
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Aneira Pharma, Inc.
Androgenetic Alopecia
Study To Determine Safety & Efficacy Of Autologous Human Platelet Lysate in Androgenetic Alopecia After Hair Transplant
This is a multicentre, open label, randomized, pilot study to evaluate safety and efficacy of Human Platelet Lysate (HPL) in subjects with Androgenetic Alopecia undergoing hair transplantation.
- Trial name
- NCT01644422
- Testing
- Autologous Human Platelet Lysate, Standard hair follicle transplant
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Kasiak Research Pvt. Ltd.
Androgenetic Alopecia
Minoxidil Response Testing in Males With Androgenetic Alopecia
Topical minoxidil is the most common drug used for the treatment of AGA in men. While topical minoxidil exhibits a good safety profile, the efficacy in the overall population remains relatively low i.e., 30-40% re-grow hair.
- Trial name
- NCT02198261
- Testing
- 5% minoxidil topical foam
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 300 people
- Sponsor
- Applied Biology, Inc.
Androgenic Alopecia
Assessment of the Effects and Tolerance of the RV4986A Lotion in Men With AGA After Hair Transplant
Alopecia involves a diminution of visible hair that can have significant psychosocial effects and impairment of quality of life.
- Trial name
- NCT06576492
- Testing
- RV4986A lotion
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Androgenetic Alopecia (AGA)
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
This study is designed to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.
- Trial name
- NCT07327359
- Testing
- OLX72021
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Olix Pharmaceuticals, Inc.
Androgenetic Alopecia
Comparing Standard Platelet-Rich Plasma and Light-Enhanced Platelet-Rich Plasma for Treating Hair Loss in Androgenetic Alopecia: A Randomized Controlled Trial
The goal of this clinical trial is to compare 3 different types of PRP in androgenetic alopecia patients. The main questions it aims to answer: Does Redlight enhanced, Blue light enhanced, or traditional PRP result in higher hair…
- Trial name
- NCT07739147
- Testing
- Platelet-Rich Plasma (PRP) Injections, Red-light photobiomodulation with cooling, Blue-light photobiomodulation
- Volunteers
- 30 people
- Sponsor
- Kimberly Meathrel
Androgenic Alopecia
To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin
The trial was a multicentre, randomised, double-blind, placebo controlled phase 2 trial. 60 healthy bald male subjects diagnosed with alopecia, who are between 18 and 55 years old and provide written informed consent were…
- Trial name
- NCT03467412
- Testing
- FOL-005
- Where
- 2 sites in Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Follicum AB
Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)
This is a Phase 3, prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial designed to evaluate the efficacy and safety of N1087 in women with female pattern hair loss (FPHL).
- Trial name
- MINORA-WOMEN (NCT07303322)
- Testing
- N1087
- Volunteers
- 372 people
- Sponsor
- Eurofarma Laboratorios S.A.
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899)
Evaluate the ability of injections of Ji Gami(TM) and Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451112
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia
the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending
The study is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability and PK of KX-826 following topical multiple ascending dose administration.
- Trial name
- NCT04502901
- Testing
- KX0826
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia
This is a first-in-human study of ABS-201, a new investigational medicine, in healthy adult men and women. Its main purpose is to find out whether ABS-201 is safe and well tolerated, as well as to understand how the body…
- Trial name
- NCT07317544
- Testing
- SAD IV Dose 1 - 150mg ABS201 IV Single Dose, ABS-201 SC Multiple Doses
- Where
- 5 sites in Australia
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Absci Pty Ltd.
Androgenetic Alopecia
A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia
This multi-center, randomized, double-blind, placebo-controlled study, conducted in Turkey, will assess the efficacy and safety of topical SM04554 solution (0.15% and 0.25%) applied daily to the scalp of male androgenetic…
- Trial name
- NCT03742518
- Testing
- Topical SM04554 0.15% solution, Topical SM04554 0.25% solution, Topical vehicle solution
- Where
- 14 sites in Turkey (Türkiye)
- Volunteers
- 675 people
- Sponsor
- Biosplice Therapeutics, Inc.
Alopecia, Androgenetic
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss
The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and safe and how well the drug is tolerated by subjects.
- Trial name
- SCALP1 (NCT05910450)
- Testing
- Clascoterone 5% solution, Vehicle solution
- Where
- 24 sites in United States, Georgia
- Volunteers
- 703 people
- Sponsor
- Cassiopea SpA
Androgenetic Alopecia
A Phase 2a Trial of FOL-005 Topical Formulations to Investigate Hair Growth Potential and Safety in Healthy Male Volunteers
This exploratory phase IIa, double blind, randomized, vehicle controlled, multicenter dose-finding trial will evaluate the safety, tolerability, and efficacy of FOL-005 topical formulation (at 0.1%, 0.5% and 1.5% strength)…
- Trial name
- NCT04774874
- Testing
- Topical formulation
- Where
- Germany
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- Follicum AB
Androgenetic Alopecia (AGA), Chronic Telogen Effluvium
Evaluation of the Dietary Supplement Efficacy Against Hair Loss in Subjects Suffering From Hair Loss
The goal of this study was to learn if dietary supplement in capsules and drinkable works to help hair loss in volunteers with chronic telogen effluvium and androgenetic alopecia and learn about its safety.
- Trial name
- NCT07358403
- Testing
- Dietary supplement capsule use for hair loss, Dietary supplement drinklable use for hair loss
- Where
- Italy
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Lacer S.A.
Alopecia, Alopecia, Androgenetic
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA).
- Conditions
- Alopecia, Alopecia, Androgenetic, Baldness
- Trial name
- NCT01904721
- Testing
- Bimatoprost Solution 1, Bimatoprost Solution 2, Bimatoprost Vehicle
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- Allergan
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669)
Evaluate the injections of Ji Gami(TM) and Ji Gami(TM) DO, where cells are expanded ex vivo from scalp, to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451177
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 3 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute